{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-122564","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.293623+00:00","generated_at":"2026-05-16T12:43:11.082754+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ocular Therapeutix enters quiet period for SOL-1 Phase 3 trial; data on track Q1 2026","bullets":["Quiet period for SOL-1 Phase 3 trial of AXPAXLI (wet AMD) begins December 20, 2025.","Next investor communication expected early February 2026 with Q4/FY2025 results.","SOL-1 data remain on track for release in the first quarter of 2026.","No financial results or clinical data provided; no exhibits attached."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-122564","json":"https://secwatch.observer/filing/0001104659-25-122564.json","markdown":"https://secwatch.observer/filing/0001104659-25-122564.md","text":"https://secwatch.observer/filing/0001104659-25-122564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925122564/0001104659-25-122564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465925122564/tm2533889d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:43:11.082754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}